In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…
Search results for: psoriasis
Moderate Liver Enzyme Elevation Found in Patients With & Without Hepatic Steatosis
Limited data are available on liver enzyme elevation in patients with RA, PsA and psoriasis being treated with tofacitinib and methotrexate. But early study findings are shedding light on the nature and risks of liver enzyme levels in these patients…
Bimekizumab Promising for PsA
CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…
Study Assesses the Role of Genetics & the Gut in Reactive Arthritis
Genes may predispose people to have certain microbial signatures in their gut that, in turn, make them susceptible to developing reactive arthritis. This is the main finding of a recent study in which researchers investigated whether perturbations in the intestinal microbiome play a role in susceptibility to reactive arthritis in the face of triggers, such…
New Guideline for the Treatment of Psoriatic Arthritis
ACR guidelines include recommendations for the management of patients with particular conditions or diseases. Guidelines are developed using a systematic process and are based on available evidence and the clinical experience and expertise of rheumatologists and other interested stakeholders. In the January issue of Arthritis & Rheumatology, Arthritis Care & Research and the Journal of…
When Immunodeficiency & Autoimmunity Coexist
When a patient has both primary immune deficiency and autoimmune disease, the combination can lead to life-threatening complications. Here are some insights into the challenges of diagnosing and treating this rare subset of patients…
New PsA Guideline Released
The ACR & the National Psoriasis Foundation (NPF) have published a joint Guideline for the Treatment of Psoriatic Arthritis (PsA). The guideline will serve as an aid to practitioners managing active PsA in patients.
Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes
New research shows that patients with psoriatic arthritis (PsA) have a greater risk for developing type 2 diabetes than patients with psoriasis alone or the general population. Researchers also found that PsA and psoriasis patients have a similar rate of increased risk for cardiovascular disease…
Identifying Cardiovascular Risk Factors in Psoriatic Arthritis
Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardiovascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…
2018 ACR Awards of Distinction & ACR Masters
CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. You’ll also find the 2018 Masters list. In the next issue,…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 55
- Next Page »